Navigation Links
Precious metal could lead to next generation of cancer treatments
Date:12/8/2008

A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by University of Warwick researchers.

The metal, osmium, is closely related to platinum, which is widely used to treat cancers in the form of the drug cisplatin. Most famously, the cyclist Lance Armstrong was treated with cisplatin for testicular cancer.

Now the researchers, based in the Department of Chemistry, at the University of Warwick, are working closely with Warwick Ventures, the university's technology transfer office, to seek partners to help develop the potential of osmium through more extensive biological tests. The team will be presenting their work on 9 December at the national university technology showcase event, Bioversity.

Professor Peter Sadler, of the Department of Chemistry, explained: "Although cisplatin has been proven to be a very successful treatment; it is not useful for all kinds of cancer. It is also quite a toxic therapy, which can produce side effects and, from a clinical point of view, cells can also become resistant to platinum."

Osmium, with its special chemical properties, offers a new potential solution to an unmet clinical need. It has shown huge promise in treating several different types of cancer cell, including ovarian and colon cancers which have been developed and tested in the laboratory. The metal also has another advantage in that it is a much cheaper alternative to platinum.

Professor Sadler, along with post-graduate researcher Sabine van Rijt, is working to develop new compounds using Osmium, which they hope will lead to the development of drugs which could be used in combination therapies alongside existing drugs such as cisplatin.

"The compounds we have been developing are very promising," says Sabine van Rijt. "We're building a picture of how different compounds might interact with DNA in cancer cells. By making changes to the coating, or ligand, on the metal, we can also affect not just how it interacts, but the rate of interaction.

During this design process we can also make changes which can control the activity of the compound."

She added: "Another advantage is that these compounds are not cross-resistant with platinum. They kill the cancerous cells in a different way, so they could be used alongside platinum in combination therapies."

The team's research is being presented on 9 December at Bioversity 2008, a national university technology showcase event. Bioversity is part of the biotechnology conference, Genesis 2008, organised by The London Biotechnology Network.


'/>"/>

Contact: Peter Dunn
p.j.dunn@warwick.ac.uk
44-024-765-23708
University of Warwick
Source:Eurekalert

Related medicine news :

1. Precious Time - Scientists discover how long heart failure patients can expect to live
2. Mothers Day Gives Woman Reason to Celebrate Lifes Most Precious Gift
3. MIPSolutions, Inc. Reduces Expense and Development Time Associated With Precious Metal Extraction
4. Cornell efficiency experts seek to save precious minutes in deploying ambulances
5. Donate Blood - A Simple and Precious Lifegiving Gift
6. Biosensors to probe the metals menace
7. Drug-Coated Stents No Riskier in Long Run Than Bare Metal Ones
8. Heavy metal slips down UK air quality charts
9. Drug-Coated Stents Better Than Bare-Metal Ones in Complex Cases
10. New sensor system improves detection of lead, heavy metals
11. Novel organic metal hybrids that will revolutionize materials science and chemical engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... GA (PRWEB) , ... July 21, 2017 , ... ... asset protection and financial consultation services to families and business owners in the ... drive to raise support for children overcoming sexual assault and physical abuse. , ...
(Date:7/21/2017)... Helena, AL (PRWEB) , ... July 21, 2017 ... ... that offers insurance assistance and financial planning services to communities in the greater ... that promises to provide resources to underprivileged young people in the region. , ...
(Date:7/21/2017)... ... 21, 2017 , ... Hospital M&A activity slowed in the second quarter of ... acquisitions rose to 23 in the second quarter, up 15% from the 20 publicly ... announced deals in the year-ago second quarter. Only four of the transactions disclosed a ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... a $5,000 grant from the C. R. Bard Foundation, Inc. to ... Somerset Hills , a service available through the nonprofit home care agency. Using ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)...  Bayer has awarded grants totaling more than $2 million ... prestigious Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and ... and Uniformed Services University of the Health Sciences in ... recipients were announced last night during a reception at the ... Berlin, Germany . ...
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)... , July 10, 2017 The Institute ... test methods, is the recipient of a VITROCELL® inhalation ... PETA International Science Consortium. The device, which is designed ... to expose human lung cells to airborne test materials ... will use the VITROCELL® system for testing combustible tobacco ...
Breaking Medicine Technology: